Pirofel

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pirofel

Pirofel is a widely recognized proprietary name for a medicine containing the active ingredient Piroxicam. It is definitively classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID) and is a core anti-inflammatory agent.

Property Description
Active ingredient Piroxicam (a single agent product)
Form Capsules, tablets, gels, creams, and ampoules
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General purpose Symptomatic relief of pain and swelling
Origin Synthetic compound (oxicam derivative)

What Type of Medicine is Pirofel (Piroxicam)?

Pirofel's active ingredient, Piroxicam, is a synthetic compound that belongs to the oxicam derivative chemical family, a classification defined by its molecular structure. Its pharmacological class is designated as an NSAID, which means the drug acts by inhibiting the body's synthesis of substances responsible for triggering inflammation and pain. Piroxicam has a relatively long plasma half-life compared to many other NSAIDs, a property that allows its therapeutic effects to be sustained over a longer period.


What is Pirofel Made Of, and What Forms Are Available?

The fundamental composition of Pirofel is the Piroxicam base, which may also be formulated as the highly soluble complex, Piroxicam beta-cyclodextrin, alongside inert base/vehicle components. This beta-cyclodextrin formulation is specifically engineered to ensure a more rapid absorption from the digestive tract, a differentiating factor when quick symptomatic relief is desired. Pirofel is available in diverse dosage forms for both systemic and local administration, including oral forms like capsules and tablets, as well as topical gel or cream.


What is the General Purpose of Pirofel's Anti-Inflammatory Effect?

The general purpose of Pirofel is to mitigate symptomatic manifestations of inflammation, such as pain, swelling, and stiffness typically seen in musculoskeletal disorders. Piroxicam is used to provide relief comparable to other well-established traditional NSAIDs. Its core physiological actions are a strong anti-inflammatory effect and a reliable analgesic effect (pain relief) by inhibiting the synthesis of prostaglandins.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Pirofel?

Possible Side Effects and Safety Information

The safety profile of Pirofel, based on government regulatory documentation, includes serious risks and common adverse reactions categorized by frequency and body system.

Serious Adverse Reactions

Official regulatory documents emphasize that Pirofel may increase the risk of serious, potentially fatal cardiovascular thrombotic events (such as myocardial infarction and stroke) and serious gastrointestinal adverse events (including bleeding, ulceration, and perforation). These risks may occur early in treatment and may increase with the duration of use.

Less common but serious documented reactions include severe skin conditions (such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis), hepatotoxicity, renal toxicity, and anaphylactic reactions.

Common Adverse Reactions

The most frequently reported side effects (with an incidence of greater than 2% in clinical trials) often involve the gastrointestinal and nervous systems, and include:

  • Nausea, constipation, diarrhea, flatulence, abdominal pain
  • Headache, dizziness
  • Edema
  • Rash

Population-Specific Safety Considerations and Restrictions

Contraindications define absolute restrictions on the use of Pirofel in specific high-risk settings. The drug is strictly contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. It is also contraindicated in patients with a known history of hypersensitivity to Pirofel or other NSAIDs (e.g., aspirin-sensitive asthma).

Use of Pirofel at or after 20 weeks of pregnancy may result in fetal toxicity. Patients with pre-existing heart disease or a history of gastrointestinal bleeding have an increased risk of serious events.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Pirofel (Piroxicam) overdose is defined by the potential for severe systemic and organ toxicity.

Feature Description
Documented overdose presentations Manifestations are broad, affecting the central nervous, gastrointestinal, renal, and cardiovascular systems. Signs may include severe headache, agitation, blurred vision, seizures, nausea, vomiting, stomach pain, shock, and little to no urine production.
Physiological systems affected Gastrointestinal tract (potential bleeding, ulceration, and perforation), Central Nervous System (progressing to coma), and Renal/Cardiovascular function.
Emergency-response statements Management is strictly defined as symptomatic and supportive treatment, including the administration of activated charcoal and continuous monitoring of vital signs.
When immediate medical help is required Seek immediate medical attention or emergency services immediately for any suspected overdose or the manifestation of severe, potentially life-threatening symptoms.

Overdose classifications (high-level)

Classification Description
Severity classification The overdose carries a risk of severe and life-threatening outcomes, including fatal GI events, profound CNS depression, and acute renal impairment.
Overdose-context constraints No specific antidote is known to reverse the effects of Piroxicam overdose.

Official overdose statements:

  • Overdose may present with CNS manifestations such as confusion, convulsions, or a progression to coma.
  • Serious GI effects, including bleeding and perforation that can be fatal, are a documented risk of overdose.
  • Systemic signs include low blood pressure (shock) and little to no urine production.

Connection to the overall overdose profile:

Regulatory documents define the Pirofel overdose profile by emphasizing the potential for severe multi-system toxicity, particularly detailing life-threatening GI and CNS outcomes. This established severity dictates the explicit regulatory requirement to seek immediate medical help, underscoring that management consists of required hospital-level support, continuous vital sign monitoring, and procedural measures rather than a specific antidote.

Therapeutic Uses of Pirofel

What Pirofel Treats: Main Uses and Benefits


Pirofel (Piroxicam) is commonly used across conditions characterized by periods of heightened symptoms, including rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It is relevant for easing the persistent, daily manifestations of joint pain, tenderness, and stiffness. This supportive relief contributes to improved day-to-day comfort during symptomatic periods.

The medication is also applied in clinical settings that involve acute or unstable symptom patterns, such as during a severe flare-up of gouty arthritis. It is applied in contexts where pronounced swelling and intense discomfort create noticeable interference, offering supportive relief that may help patients cope more steadily with these acutely disruptive manifestations. By easing symptoms related to inflammatory or irritative states, Pirofel plays a role in managing symptoms that directly limit movement.

“It is relevant in contexts marked by increased discomfort or tension.”


Quick Fact: Symptomatic Support: Addressing Pain and Stiffness

Pirofel is commonly used to help with symptoms that create noticeable functional strain, particularly chronic pain and morning stiffness associated with inflammatory joint conditions. It assists with maintaining comfort and easing functional strain, which supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview of Piroxicam

Eligibility and Restrictions for Use

Who Can and Cannot Use Pirofel? — Official Eligibility Profile

This section outlines the official eligibility and non-eligibility requirements for the use of Pirofel (Piroxicam), strictly based on governmental regulatory documents.


Absolute Contraindications (Must Not Use)

Use of Pirofel is strictly forbidden (contraindicated) for individuals with:

  • A known allergy or hypersensitivity to piroxicam, aspirin, or any other Non-Steroidal Anti-Inflammatory Drug (NSAID).
  • Active gastrointestinal ulceration, bleeding, or a confirmed history of gastrointestinal perforation or hemorrhage.
  • The setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Severe, uncontrolled heart failure, or severe renal or hepatic failure.
  • Pregnancy during the third trimester (starting at 30 weeks gestation).

Conditional Use and Restrictions

Use requires caution and close monitoring for patients with pre-existing conditions:

  • Cardiovascular: Individuals with hypertension or mild-to-moderate congestive heart failure.
  • Renal/Hepatic: Patients with mild or moderate kidney or liver impairment.
  • Age: The elderly population (over 65) may require reduced dosage due to higher risk of side effects.

Age and Developmental Status

  • Pediatric Population: Safety and efficacy have not been established for use in children or adolescents (generally under 18 years).
  • Lactation: Use during breastfeeding is not recommended as the drug is secreted into breast milk.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section summarizes the official interaction patterns for Pirofel (Piroxicam) as documented in governmental regulatory sources. All documented interactions strictly relate to co-administration risks or exposure modification.


Official Regulatory Classifications

Classification Interacting Agents (Examples)
Formally Contraindicated Oral Anticoagulants (e.g., warfarin), Other NSAIDs (including COX-2 inhibitors), Analgesic Doses of Aspirin
Increased Bleeding Risk Glucocorticosteroids, SSRIs/SNRIs, Anti-platelet Agents, Deferasirox
Effect Diminished ACE Inhibitors/ARBs, Diuretics

Exposure and Population Notes

Pirofel is primarily metabolized via the CYP2C9 enzyme. Regulatory documentation notes that individuals identified as CYP2C9 poor metabolizers may have abnormally high plasma levels of Piroxicam due to reduced metabolic clearance. This exposure modification is officially considered when determining administration.

Interactions with antihypertensives (such as ACE Inhibitors and ARBs) may reduce the efficacy of the blood pressure medicine and increase the risk of renal function deterioration, particularly in elderly, volume-depleted, or renally impaired patients.

Regulatory sources also document that the consumption of excessive amounts of alcohol is a risk factor that officially contributes to a heightened risk of serious gastrointestinal complications and bleeding when co-occurring with Pirofel.

Mechanism of Action

Enzyme Inhibition and Prostaglandin Modulation

Pirofel's primary mechanism involves reversible inhibition of Cyclooxygenase (COX) enzymes in cells, which are critical catalysts in the Arachidonic Acid Cascade. By blocking the enzyme's active site, Pirofel suppresses the cellular synthesis of prostaglandins—mediators that typically amplify physiological responses. This core action limits the propagation of signaling cascades that are characterized by elevated local mediator concentrations.


Modulating Central and Peripheral Signaling

This action results in the modulation of physiological processes at both local tissue sites (peripheral) and within the brain (central). Peripherally, Pirofel modulates pathways that contribute to nerve sensitization. Centrally, the mechanism engages systems that control the body's thermoregulatory set point in the hypothalamus. These dual actions result in the modulation of overactive physiological responses and contribute to a regulated state within the targeted neural and chemical pathways.

Dosage and Administration Information

Instruction Map: How to use Pirofel — General Administration Guidelines

The general principles for using Pirofel are defined by standardized dosing schedules that establish the route, frequency, and maximum limits for administration.

Feature Common Administration Parameters
Route of administration Primarily Oral (capsules/tablets); also used for Intramuscular (IM) Injection and Topical (gel/cream) administration.
Dosing schedule For chronic conditions, the standard maintenance dose is 20 mg taken once daily. The maximum recommended daily dose for chronic use is 20 mg.
Timing in relation to meals Oral forms are taken with food or a full glass of water to aid proper administration.
Preparation requirements Oral capsules are swallowed whole; they are not crushed, broken, or chewed.
Age-group administration rules Older Adults: The lowest effective dose for the shortest duration is considered. CYP2C9 Poor Metabolizers: Dose reduction may be necessary.
Missed-dose rules If a dose is missed, it is generally addressed by taking the dose as soon as remembered, unless it is almost time for the next scheduled dose.
Special procedural conditions Chronic Use: The benefit of continued treatment is reassessed within 14 days of initiation and monitored frequently thereafter.

Overview of Usage Parameters

General step sequence:

  • Verify Dose and Frequency: The dose is determined by the condition, typically 20 mg taken once daily for maintenance.
  • Ensure Proper Intake: Oral administration involves swallowing the capsule whole with food or water.
  • Monitor Treatment Duration: Treatment for chronic conditions is professionally reassessed within 14 days of starting.

The usage protocol for Pirofel is structured around its long half-life, which enables a once-daily systemic dose. This protocol defines the established dose limits, such as the maximum 20 mg maintenance dose, and the requirement for clinical re-evaluation of long-term use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pirofel

The clinical evaluation of Pirofel (Piroxicam) is based on findings from decades of formal clinical trials, primarily Randomized Controlled Trials (RCTs) and comprehensive meta-analyses that pool data from multiple studies. Research has explored the evaluation of Pirofel in conditions characterized by periods of heightened symptoms, such as chronic inflammatory and degenerative joint conditions.


Evidence Summary for Osteoarthritis Studies

Research involving Pirofel in Osteoarthritis (OA) has largely relied on short-term, parallel-group Randomized Controlled Trials. These studies explored how symptoms change over time when Pirofel was compared against a placebo or against other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). The populations studied were typically adults with symptomatic, confirmed OA, including a significant presence of older adults in the research cohorts.

The trials monitored outcomes related to physical discomfort, such as measurements of pain intensity using standardized scales, and outcomes reflecting daily functioning, such as measurements of the duration of morning stiffness and various functional capacity indices. Researchers documented measurements of these outcomes over the short-term follow-up periods, which commonly ranged from a few weeks to three months. Evidence contributes to understanding symptom patterns, based on measurements observed in the studies.


Evidence Summary for Rheumatoid Arthritis Studies

For Rheumatoid Arthritis (RA), studies used comparable RCT methodologies and systematic reviews to examine Pirofel's evaluation in conditions characterized by periods of heightened symptoms. The research explored short-term symptom changes in adult populations with active RA.

The primary outcomes monitored were outcomes linked to inflammatory or irritative states. Researchers measured the number of tender and swollen joints and measured the length of time patients experienced morning stiffness. Research highlights changes measured during the study period in these specific signs of disease activity. Patterns observed in the studies were consistent with the expected research findings for this class of medicine. The evidence contributes to understanding symptom patterns, but the follow-up durations were often limited to short intervals.


Evidence Summary for Other Chronic and Acute Inflammatory Conditions

Pirofel was evaluated in research exploring outcomes related to Ankylosing Spondylitis (AS) and other inflammatory joint conditions, using controlled trials to explore short-term changes in spinal pain and measures of functional mobility. Research in this area examines outcomes reflecting daily functioning in conditions marked by functional limitations.

Additionally, Pirofel was observed in research contexts involving acute episodes where symptoms become more noticeable, such as acute flare-ups of Gouty Arthritis. These studies were necessarily very short-term (often less than a week) and primarily monitored rapid measurements of pain relief and reductions in swelling. Data show patterns related to temporary physiological imbalance in these acute settings.


Long-Term Studies and Follow-up Durability

While the primary evidence concerning symptomatic effects for Pirofel comes from short-term studies lasting a few weeks or months, observational cohorts and some extended-duration trials have been used for evaluation over time. These studies focus on outcomes related to systemic or functional imbalance that may occur with continuous treatment.

However, the evidence is limited, and the follow-up durations were limited in the most rigorous controlled settings. Consequently, the durability of symptomatic response over many years is not fully established by the existing evidence base, and long-term outcomes are not well characterized. Research highlights what is known—and what is still uncertain—about using the medicine over extended periods.


Evidence in Special Populations

The research has included some focus on specific patient groups, such as older adults (geriatric population), who were often participants in the main OA and RA clinical trials. Studies examined outcomes related to physical discomfort in these age groups. Some studies reported patterns observed in older adults that were generally similar to those observed in younger adult cohorts. Variability in individual response was documented.

Limited information is also available from smaller studies and clinical experience regarding the evaluation of Pirofel in certain pediatric populations, such as for Juvenile Idiopathic Arthritis (JIA). For this evaluation, sample sizes were modest, meaning the data for this group remain insufficient, and the certainty remains low. Furthermore, specific studies related to pregnancy-related populations are not a central component of the evidence base.


Research Gaps and Areas of Uncertainty

A major limitation across the research landscape is that the results apply mainly to the populations studied and predominantly reflect short-term outcomes related to symptomatic changes. Research provides context but not individual predictions of response, and findings describe group patterns, not personal outcomes.

Evidence quality varies across studies, and research comparing Pirofel against certain newer anti-inflammatory drugs is lacking in large-scale trials. The research does not determine whether an individual will respond similarly to the group averages. The need for more definitive, long-term studies to better characterize the durability of response and the long-term patterns of change remains a recognized area of uncertainty.

Frequently Asked Questions (FAQ)

Common questions about Pirofel (FAQ)

Q: How long after starting Pirofel should I expect to feel an effect?

Official patient information indicates that the active ingredient reaches peak levels in the blood within a few hours. Evidence suggests that for chronic conditions, it may take up to one or two weeks for measurable changes in symptoms to be noted in studies. This is a common pattern for medicines in this class.

Q: Is it normal to feel a bit dizzy when first taking Pirofel?

According to the official product information, dizziness is classified as a common adverse reaction that was reported by patients in clinical trials. If this or any side effect occurs, patients are generally advised to note their symptoms.

Q: What should I do if my side effects from Pirofel feel worse than expected?

Official guidance states that if you experience any signs of a serious problem, such as a severe gastrointestinal complication or persistent liver function abnormality, the medication should be discontinued immediately. Additional medical evaluation by a healthcare professional is officially recommended following discontinuation.

Q: What type of inflammatory conditions is Pirofel commonly used for?

Regulatory documents state that Pirofel is officially indicated for the symptomatic relief of chronic inflammatory and degenerative joint conditions. This commonly includes Osteoarthritis (OA), Rheumatoid Arthritis (RA), Ankylosing Spondylitis, and acute periods of heightened symptoms such as Gouty Arthritis flares.

Q: Why is Pirofel sometimes prescribed when other pain relievers haven't worked?

Official information notes that Pirofel has a distinctively long plasma half-life compared to many other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). This pharmacological property allows for a sustained concentration in the body that supports once-daily systemic dosing, a factor that may be considered in treatment choice.

Q: Are there any specific warnings for people who have heart conditions and use Pirofel?

Yes, the official warnings state that Pirofel may increase the risk of serious cardiovascular events, such as heart attack and stroke. The regulatory documents state that blood pressure monitoring should be considered for patients with conditions such as uncontrolled hypertension or congestive heart failure.

Q: Does Pirofel affect kidney function?

Regulatory documents indicate that Pirofel, like other NSAIDs, can lead to functional renal (kidney) impairment, which is usually reversible once the medication is stopped. Monitoring of kidney function may be necessary for patients who have pre-existing risk factors, according to regulatory notes.

Q: Is Pirofel available over the counter in some countries?

In the United States, Pirofel (piroxicam) is primarily available only with a prescription from a doctor. Regulatory status can vary globally, and some lower strength topical forms of the active ingredient may be available over the counter in specific jurisdictions.

Q: Does taking Pirofel require regular blood tests?

Regulatory documents do not mandate general regular blood testing for all patients on Pirofel. However, official information does recommend monitoring of renal (kidney) and liver function for individuals who have pre-existing risk factors.

Q: Is Pirofel the same kind of medicine as Advil or Tylenol?

Pirofel is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), a class that includes medicines like ibuprofen (Advil). However, Pirofel is a chemically distinct compound within this group. Acetaminophen (Tylenol) is a pain reliever but is not classified as an NSAID.

Q: Why do some people say Pirofel is a stronger pain reliever?

Official studies indicate that Pirofel is associated with changes in symptoms similar to those observed with other traditional NSAIDs. Official drug documents do not use comparative claims regarding a drug's 'strength,' focusing instead on its documented efficacy and safety profile.

Q: Can Pirofel affect my sleep patterns?

Yes, official safety information reports that effects on the central nervous system have been documented. Insomnia (difficulty sleeping) is listed as an adverse reaction that has been reported in postmarketing data.

Q: Is it possible to have a side effect that is not listed in the patient leaflet?

Official documents include a section for postmarketing reports of adverse reactions, which means that events not observed in initial clinical trials may be reported later. Official drug information may be updated to reflect these observations.

Q: Is Pirofel used to treat fevers?

Pirofel belongs to the Nonsteroidal Anti-Inflammatory Drug (NSAID) class of medicines. The mechanism of action for this class includes regulating the body’s thermal set point, a physiological action that helps to relieve fever. However, the medicine is primarily officially indicated for inflammatory conditions.

Q: Can Pirofel cause an allergic reaction, and what are the signs?

Yes, Pirofel can cause a severe allergic reaction, and is strictly contraindicated in patients with a history of hypersensitivity to it or other NSAIDs. The official information lists signs that require immediate attention, such as swelling of the face or throat, trouble breathing, or hives.

Q: Is there a generic version of Pirofel?

Yes, Pirofel contains the active ingredient Piroxicam. Regulatory bodies, such as the U.S. FDA, have approved generic versions of the capsule formulation of this active ingredient.

Q: Why do people use Pirofel for conditions that don't seem like inflammation?

Pirofel is only officially indicated in regulatory documents for conditions that require pain relief and/or anti-inflammatory activity. Any usage outside of its officially approved indications is not addressed by the formal prescribing information.

Q: Do different strengths of Pirofel have different side effect profiles?

Official documentation notes that administering doses greater than 20 mg per day is associated with an increased risk of certain gastrointestinal side effects and toxicity. This regulatory guidance indicates that the risk of some side effects may be associated with the dosage level used.

Q: Does Pirofel make you drowsy?

While drowsiness is not one of the most frequently reported common side effects, official adverse reaction reports do include instances of somnolence (drowsiness) and sedation. These effects on the central nervous system have been documented.

Q: Is it true that Pirofel can cause a serious skin reaction?

Yes, official regulatory documents list severe skin conditions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as less common but serious documented reactions. Official guidance includes advice that the medication should be stopped and medical help sought if a rash develops.

Q: Does Pirofel have a risk of dependence or addiction?

Pirofel is a Nonsteroidal Anti-Inflammatory Drug (NSAID) and is not classified as a controlled substance by U.S. regulatory bodies. Official information does not indicate a known risk of dependence or addiction associated with its use.

Q: Are there specific symptoms that mean I should stop taking Pirofel immediately?

Official guidance states that treatment must be immediately discontinued at the first appearance of certain symptoms. These include any severe skin rash or signs of a gastrointestinal event, such as black or bloody stools or sudden severe stomach pain.

Q: Are there specific patient groups where Pirofel is monitored more closely?

Yes, official documents describe several patient groups that require caution and close monitoring. These include older adults, individuals with pre-existing conditions like hypertension or heart failure, and patients who are known or suspected to be CYP2C9 poor metabolizers.

Q: What is the typical timeframe for reviewing the effectiveness of Pirofel?

Official instructions state that when Pirofel is used for chronic conditions, the benefit of continuing treatment must be reassessed by a physician within 14 days of the start date. Safety must also be re-evaluated periodically thereafter.

Q: Is it normal for the pain to return quickly after the effect of Pirofel wears off?

Pirofel has a relatively long plasma half-life of approximately 50 hours, which is a differentiating factor compared to many other NSAIDs. The long half-life of Pirofel is a factor that supports a sustained concentration in the body.

Q: How quickly is Pirofel absorbed into the body?

According to the pharmacokinetics information in regulatory documents, the active ingredient in Pirofel is absorbed after oral administration, typically reaching its peak concentration in the body within approximately three to five hours following intake.

Q: Why do some patient forums mention a feeling of restlessness with Pirofel?

Official adverse reaction reports include instances of nervousness and sometimes mention akathisia (an inability to sit still) in connection with the central nervous system. These documented effects may align with the feeling of restlessness described in some patient communities.

Q: What is the evidence regarding Pirofel's long-term safety profile?

The official safety profile notes that the risks of serious adverse events, including cardiovascular thrombotic events and gastrointestinal complications, may increase with the duration of use. Because of this, the benefit and safety of long-term treatment must be frequently monitored by a physician.

How should Pirofel be stored and disposed of?

Storage and Disposal of Pirofel (Piroxicam) — Official Regulatory Information

Scope Item Official Regulatory Requirement
Storage Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with a maximum limit of 30 C
Environmental Protection Keep the medicine away from excess heat and moisture and protect from light. It is mandatory to keep from freezing
Packaging Rules Store the medication in the container it came in, which must be kept tightly closed
Child Safety Keep out of the sight and reach of children
Disposal Instructions Do not throw away any medicines via wastewater or household waste. Ask a pharmacist how to dispose of unused or outdated medicine to help protect the environment

Connection to the overall storage/disposal profile: Regulatory labeling defines the storage profile of Pirofel by specifying strict temperature controls, requiring storage within a defined room temperature range while explicitly prohibiting freezing. To maintain product integrity, official guidance mandates protection from light and moisture, and requires keeping the product in its original, tightly closed container. Unused product must be discarded via appropriate pharmaceutical waste protocols, avoiding disposal into domestic waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pirofel found in:

A-Z Index: